Navigation Links
Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
Date:7/16/2008

h low toxicity.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule called Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

About UCSF

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. For more information, please see http://www.ucsf.edu.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not sup
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
2. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
3. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
6. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
7. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
8. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
9. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
10. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
11. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DALLAS , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com ... to its store . (Photo: ... consumption upgrade and policy support, China,s ... the years, with total market size rising from 3.28 ...
(Date:1/15/2014)... and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition ... Analysis, Size, Share, Growth, Trends And Forecast, 2013 - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Dental ... order to treat dental impairments, for tooth restoration and ...
(Date:1/15/2014)... today announced it has established a relief fund ... that has gripped much of the nation. AARP and its ... support these emergency relief efforts AARP and AARP Foundation will ... to $500,000 in aid. The matching program will be administered ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
... CLAREMONT, Calif., Dec. 9 The U.S. Food and ... orphan drug workshop series--an opportunity for biotechnology companies, pharmaceutical ... days creating applications for orphan status designation, under the ... Development (OOPD). The first workshop is planned for Feb. ...
... BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced ... Company,s Board of Directors. Dr. Sanders brings to BioCryst ... professor of medicine. , "We are pleased to ... P. Horovitz, Ph.D., Chairman of the Board of BioCryst Pharmaceuticals. ...
Cached Medicine Technology:FDA Launches Orphan Drug Workshop at KGI 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4
(Date:7/12/2014)... (PRWEB) July 12, 2014 The report, ... Alkyd Resins) Market by Application & Geography – Trends ... market with analysis and forecasting of market volume and ... of the derivatives separately. The market of phthalic anhydride ... in 2013 to $8,415.89 million by 2018, with a ...
(Date:7/12/2014)... 2014 In this cognitive ... assessment and training’ is defined as solution ... or enhance cognitive functions. These solutions are ... dementia screening, clinical trials, driver’s safety, rehabilitation, ... assessment, brain training, and employers’ assessment and ...
(Date:7/12/2014)... The fastest-growing mobile technology is LTE (Long Term Evolution). ... continues to grow due to the rapid evolution of ... data traffic, which is a major driver for the ... Measurement equipment comply with industry standards, and services which ... Market is estimated to grown from $3.75 billion in ...
(Date:7/12/2014)... 2014 (HealthDay News) -- If you make exercise fun, you,ll ... one experiment, 56 adults were led on a 1.4-mile walk ... or a scenic walk. The participants were given lunch after ... exercise outing ate 35 percent more chocolate pudding for dessert ... In another experiment, 46 adults were given mid-afternoon snacks ...
(Date:7/12/2014)... 2014 Sean Francis, owner of the Kawartha Lakes ... to his clients. He’s also known for his support of local ... way to combine the two and is excited to announce that ... Boys and Girls Club. , The funds are the result of ... 23rd. Francis sent out emails and asked his clients to put ...
Breaking Medicine News(10 mins):Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 5Health News:Make Exercise Fun, Eat Less Afterwards 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 3
... Calif., Nov. 19 ,Natrol, Inc, (Nasdaq: NTOL ... nutritional products, and Gener8Xion Entertainment, Inc.,(OTC Bulletin Board: ... a letter of intent for a strategic,alliance to ... intends to,exclusively license the "Living Pure" brand to ...
... as World,s Leading Thoroughbred ... Radiography Review, SANTA CLARA, Calif., Nov. 19 ... doors to the,annual September Yearling Sale, the medical repository ... medical images. Beginning with 12,review workstations from Eklin Medical ...
... HCA Study Reveals Qualities of High-Performing Organizations, ... from The Beryl,Institute, titled "High Performing Organizations: Culture ... satisfaction are highly,correlated with outstanding clinical care and ... bottom line. Using the,results of a study done ...
... Nov. 19 Boston Scientific,Corporation (NYSE: BSX ... been,reached to settle claims associated with a series ... and 2006. Boston Scientific acquired,Guidant last year. This ... July 2007 to cover additional unanticipated claims. ...
... - ... 8,550 Patient Plaintiffs -, MINNEAPOLIS, Nov. 19 ... Medical Device Litigation,announced today that an amended settlement agreement ... asserted claims against Guidant,Corporation, Boston Scientific Corporation and other ...
... Flagship Global Health,Inc. (OTC Bulletin Board: FGHH), a ... priority access to, the world,s leading,doctors has added ... and services field to lead its Marketing and ... marketing and sales at Flagship,Global Health and, in ...
Cached Medicine News:Health News:Natrol, Inc. (Nasdaq: NTOL) and Gener8Xion Entertainment (BB: GNXE) Announce Strategic Alliance to Create a New Health and Wellness Division 2Health News:Natrol, Inc. (Nasdaq: NTOL) and Gener8Xion Entertainment (BB: GNXE) Announce Strategic Alliance to Create a New Health and Wellness Division 3Health News:Natrol, Inc. (Nasdaq: NTOL) and Gener8Xion Entertainment (BB: GNXE) Announce Strategic Alliance to Create a New Health and Wellness Division 4Health News:Keeneland Scales Eklin Digital Repository(TM) to 32 Medical Image Review Workstations 2Health News:Keeneland Scales Eklin Digital Repository(TM) to 32 Medical Image Review Workstations 3Health News:Boston Scientific Announces Amended Agreement to Settle Product Lawsuits 2Health News:Boston Scientific Announces Amended Agreement to Settle Product Lawsuits 3Health News:Plaintiffs Obtain $240 Million Amended Settlement In Guidant Defibrillators Products Liability Litigation 2Health News:Flagship Global Health Hires Health Care Veteran Larsen to Head Marketing and Sales 2
For the direct quantitative determination of low density lipoprotein cholesterol (LDL-C) in human serum or plasma. For in vitro diagnostic use only....
Storage temperature: 2 - 8C, linearity: 0 - 25 mg/dL, expected value: male: 3.5 - 7.0 mg/dL and female: 2.5 - 6.0 mg/dL. Available with calibrator and number of test 500....
Storage temperature: 15 - 30C, linearity: 0 - 20 mg/dL, expected value: male: 3.0 - 7.0 mg/dL and female: 2.2 - 6.2 mg/dL. Available with calibrator and number of tests 125....
The assay kit is for determination of uric acid in serum or urine. Wavelength: 600 nm. Linear range: up to 80 mg/dL....
Medicine Products: